Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem ; 100: 117610, 2024 Feb 15.
Article in English | MEDLINE | ID: mdl-38306882

ABSTRACT

Clinically available antifungal drugs have therapeutic limitations due to toxicity, narrow spectrum of activity, and intrinsic or acquired drug resistance. Thus, there is an urgent need for new broad-spectrum antifungal agents with low toxicity and a novel mechanism of action. In this context, we have successfully identified several highly promising lead compounds, i.e., aromatic N'-(salicylidene)carbohydrazides, exhibiting excellent antifungal activities against Cryptococcus neoformans, Candida albicans, Aspergillus fumigatus and several other fungi both in vitro and in vivo. Building upon these highly promising results, 71 novel N'-(salicylidene)heteroarenecarbohydrazides 5 were designed, synthesized and their antifungal activities examined against fungi. Based on the SAR study, four highly promising lead compounds, i.e., 5.6a, 5.6b, 5.7b and 5.13a were identified, which exhibited excellent potency against C. neoformans, C. albicans and A. fumigatus, and displayed impressive time-kill profiles against C. neoformans with exceptionally high selectivity indices (SI ≥ 500). These four lead compounds also showed synergy with clinical antifungal drugs, fluconazole, caspofungin (CS) and amphotericin B against C. neoformans. For the SAR study, we also employed quantitative structure-activity relationship (QSAR) analysis by taking advantage of the accumulated data on a large number of aromatic and heteroaromatic N'-(salicylidene)carbohydrazides, which successfully led to rational design and selection of promising compounds for chemical synthesis and biological evaluation.


Subject(s)
Antifungal Agents , Cryptococcus neoformans , Hydrazines , Amphotericin B , Antifungal Agents/chemistry , Candida albicans , Fluconazole , Microbial Sensitivity Tests , Hydrazines/chemistry , Hydrazines/pharmacology
2.
J Med Chem ; 62(17): 8249-8273, 2019 09 12.
Article in English | MEDLINE | ID: mdl-31369263

ABSTRACT

Recently, the fungal sphingolipid glucosylceramide (GlcCer) synthesis has emerged as a highly promising new target for drug discovery of next-generation antifungal agents, and we found two aromatic acylhydrazones as effective inhibitors of GlcCer synthesis based on HTP screening. In the present work, we have designed libraries of new aromatic acylhydrazones, evaluated their antifungal activities (MIC80 and time-kill profile) against C. neoformans, and performed an extensive SAR study, which led to the identification of five promising lead compounds, exhibiting excellent fungicidal activities with very large selectivity index. Moreover, two compounds demonstrated broad spectrum antifungal activity against six other clinically relevant fungal strains. These five lead compounds were examined for their synergism/cooperativity with five clinical drugs against seven fungal strains, and very encouraging results were obtained; e.g., the combination of all five lead compounds with voriconazole exhibited either synergistic or additive effect to all seven fungal strains.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Candida/drug effects , Hydrazones/pharmacology , Sphingolipids/antagonists & inhibitors , Antifungal Agents/chemical synthesis , Antifungal Agents/chemistry , Aspergillus fumigatus/metabolism , Candida/metabolism , Dose-Response Relationship, Drug , Drug Discovery , Hydrazones/chemical synthesis , Hydrazones/chemistry , Microbial Sensitivity Tests , Molecular Structure , Sphingolipids/biosynthesis , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...